KR100735139B1 - 글리세로-1,5-에폭시-1αβ,6-디하이드록시-시스-헥스-3-엔-2-온 또는 유도체를 함유하는 세포자멸 유도용 조성물 - Google Patents

글리세로-1,5-에폭시-1αβ,6-디하이드록시-시스-헥스-3-엔-2-온 또는 유도체를 함유하는 세포자멸 유도용 조성물 Download PDF

Info

Publication number
KR100735139B1
KR100735139B1 KR1020067021143A KR20067021143A KR100735139B1 KR 100735139 B1 KR100735139 B1 KR 100735139B1 KR 1020067021143 A KR1020067021143 A KR 1020067021143A KR 20067021143 A KR20067021143 A KR 20067021143A KR 100735139 B1 KR100735139 B1 KR 100735139B1
Authority
KR
South Korea
Prior art keywords
compound
formula
disease
activity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067021143A
Other languages
English (en)
Korean (ko)
Other versions
KR20060116034A (ko
Inventor
다츠지 에노키
준 도모노
노부토 고야마
가츠시게 이카이
히로아키 사가와
이쿠노신 가토
Original Assignee
다카라 바이오 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다카라 바이오 가부시키가이샤 filed Critical 다카라 바이오 가부시키가이샤
Publication of KR20060116034A publication Critical patent/KR20060116034A/ko
Application granted granted Critical
Publication of KR100735139B1 publication Critical patent/KR100735139B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/767—Organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/779—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
KR1020067021143A 1998-06-09 1999-06-08 글리세로-1,5-에폭시-1αβ,6-디하이드록시-시스-헥스-3-엔-2-온 또는 유도체를 함유하는 세포자멸 유도용 조성물 Expired - Fee Related KR100735139B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JPJP-P-1998-00175295 1998-06-09
JP17529598 1998-06-09
JPJP-P-1998-00223723 1998-07-24
JP22372398 1998-07-24
JP1163999 1999-01-20
JPJP-P-1999-00011639 1999-01-20
PCT/JP1999/003058 WO1999064424A1 (en) 1998-06-09 1999-06-08 Therapeutic agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067013109A Division KR100696404B1 (ko) 1998-06-09 1999-06-08 글리세로-1,5-에폭시-1αβ,6-디하이드록시-시스-헥스-3-엔-2-온 또는 유도체를 함유하는 세포자멸 유도용 조성물

Publications (2)

Publication Number Publication Date
KR20060116034A KR20060116034A (ko) 2006-11-13
KR100735139B1 true KR100735139B1 (ko) 2007-07-03

Family

ID=27279509

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020067021143A Expired - Fee Related KR100735139B1 (ko) 1998-06-09 1999-06-08 글리세로-1,5-에폭시-1αβ,6-디하이드록시-시스-헥스-3-엔-2-온 또는 유도체를 함유하는 세포자멸 유도용 조성물
KR1020007013293A Expired - Fee Related KR100620409B1 (ko) 1998-06-09 1999-06-08 글리세로-1,5-에폭시-1αβ,6-디하이드록시-시스-헥스-3-엔-2-온 또는 유도체를 함유하는 세포자멸 유도용 조성물
KR1020067013109A Expired - Fee Related KR100696404B1 (ko) 1998-06-09 1999-06-08 글리세로-1,5-에폭시-1αβ,6-디하이드록시-시스-헥스-3-엔-2-온 또는 유도체를 함유하는 세포자멸 유도용 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020007013293A Expired - Fee Related KR100620409B1 (ko) 1998-06-09 1999-06-08 글리세로-1,5-에폭시-1αβ,6-디하이드록시-시스-헥스-3-엔-2-온 또는 유도체를 함유하는 세포자멸 유도용 조성물
KR1020067013109A Expired - Fee Related KR100696404B1 (ko) 1998-06-09 1999-06-08 글리세로-1,5-에폭시-1αβ,6-디하이드록시-시스-헥스-3-엔-2-온 또는 유도체를 함유하는 세포자멸 유도용 조성물

Country Status (11)

Country Link
US (1) US6531148B1 (https=)
EP (1) EP1086952B1 (https=)
JP (2) JP3779153B2 (https=)
KR (3) KR100735139B1 (https=)
CN (1) CN1131867C (https=)
AT (1) ATE370144T1 (https=)
AU (1) AU764582B2 (https=)
CA (1) CA2334249A1 (https=)
DE (1) DE69936855T2 (https=)
TW (1) TWI244484B (https=)
WO (1) WO1999064424A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001181191A (ja) * 1999-12-24 2001-07-03 Cci Corp 慢性関節リウマチ疾患予防および治療剤
CN1418207A (zh) * 2000-01-13 2003-05-14 宝生物工程株式会社 基因表达调节失常矫正剂
AU2001294173A1 (en) * 2000-10-03 2002-04-15 Takara Bio Inc. Method of screening physiologically active substance
KR100373776B1 (ko) * 2000-12-27 2003-02-26 한불화장품주식회사 화장료 조성물
CH692180A5 (it) * 2001-06-22 2002-03-15 Gecomwert Anstalt Preparato cosmetico con azione antirughe.
WO2003024446A1 (en) * 2001-09-11 2003-03-27 Mitsubishi Pharma Corporation Oxidation stress inhibitor and method of measuring oxidation stress
US20050063995A1 (en) * 2001-10-25 2005-03-24 Spaner David E Compositions and methods for selected tumour treatment
TW200403067A (en) * 2002-04-17 2004-03-01 Takara Bio Inc Remedies
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
CA2611121C (en) * 2005-05-31 2014-01-28 Arla Foods Amba Phosphatidylserine enriched milk fractions for the formulation of functional foods
WO2012148023A1 (ko) * 2011-04-29 2012-11-01 바이올시스템즈 주식회사 무수갈락토스의 분리정제 방법
CN102321153B (zh) * 2011-09-06 2013-06-05 中国科学院成都生物研究所 一种新奥苷肽粉状固体的制备方法
KR101525298B1 (ko) * 2012-01-18 2015-06-03 고려대학교 산학협력단 3,6-안하이드로-l-갈락토오스의 제조방법 및 이의 용도
JP6241644B2 (ja) * 2013-06-05 2017-12-06 伊那食品工業株式会社 ＰＰＡＲγ発現向上剤、並びにそれを含む基礎代謝向上剤、筋肉疲労回復向上剤、ＰＰＡＲγ発現向上用医薬組成物及びＰＰＡＲγ発現向上用飲食品
KR102011721B1 (ko) * 2017-11-28 2019-08-19 고려대학교 산학협력단 포도상구균의 생육을 억제하는 한천 유래 올리고당의 용도
CN108776121B (zh) * 2018-04-08 2021-07-30 广州卡马生物科技有限公司 一种基于荧光猝灭原理对药材中抗氧剂的高通量筛选方法
CN112375110A (zh) * 2020-11-20 2021-02-19 西安乐析医疗科技有限公司 一种化合物3,4-dge的制备方法
KR102608602B1 (ko) * 2020-11-27 2023-12-01 (주)헬스코치생명공학 Ahg를 이용한 자외선에 의한 피부 주름 개선용 조성물
KR102537335B1 (ko) * 2022-08-10 2023-05-26 경북대학교 산학협력단 Ｌ­ａｈｇ를 포함하는 면역 억제용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680565A (ja) * 1992-09-03 1994-03-22 Ishihara Sangyo Kaisha Ltd 免疫機能抑制剤
JPH06182965A (ja) * 1992-12-17 1994-07-05 Toshiba Corp クリームはんだ印刷装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1202286B (de) * 1962-08-04 1965-10-07 Huels Chemische Werke Ag Verfahren zur Herstellung von beta-Pyronen
US3230233A (en) * 1964-03-04 1966-01-18 American Cyanamid Co Novel substituted 2, 3-dihydro-9-carbamo-yloxymethyl-6-methyl-pyrrolo[1, 2-a] indole-5, 8-diones
FR2541307A1 (fr) * 1983-02-23 1984-08-24 Korano Substance gelifiante semi-synthetique, son procede de preparation et ses applications, notamment dans les milieux de culture pour microorganismes
JPS62210958A (ja) * 1986-03-13 1987-09-17 Meiji Seika Kaisha Ltd 澱粉含有組成物の老化防止方法
JPH04316593A (ja) * 1991-02-21 1992-11-06 Japan Tobacco Inc Ｄ−アロサンの製造方法
JPH05565A (ja) * 1991-06-21 1993-01-08 Toyo Ink Mfg Co Ltd 皮膜形成方法
US5380834A (en) * 1992-02-06 1995-01-10 Ishihara Sangyo Kaisha Ltd. Immuno-suppressive agent
EP0873691A3 (en) * 1992-05-15 1999-07-14 Ina Food Industry Co., Ltd. Food comprising a low gel strength agar
AU666577B2 (en) * 1992-08-19 1996-02-15 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulator
JP3865801B2 (ja) * 1995-04-27 2007-01-10 株式会社ヤクルト本社 新規なβ−アガラーゼ，その製造方法及びその用途
US5834257A (en) * 1995-11-06 1998-11-10 Japan Tobacco Inc. α-agarase and production process of oligosaccharides and monosaccharides
AU727026B2 (en) * 1996-11-08 2000-11-30 Takara Bio Inc. Apoptosis inducing agent
US6809091B1 (en) * 1998-01-19 2004-10-26 Takara Bio Inc. Substances capable of inducing apoptosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680565A (ja) * 1992-09-03 1994-03-22 Ishihara Sangyo Kaisha Ltd 免疫機能抑制剤
JPH06182965A (ja) * 1992-12-17 1994-07-05 Toshiba Corp クリームはんだ印刷装置

Also Published As

Publication number Publication date
EP1086952B1 (en) 2007-08-15
WO1999064424A8 (en) 2000-04-06
DE69936855T2 (de) 2008-05-15
KR20010025107A (ko) 2001-03-26
ATE370144T1 (de) 2007-09-15
KR100620409B1 (ko) 2006-09-13
KR20060116034A (ko) 2006-11-13
KR100696404B1 (ko) 2007-03-20
DE69936855D1 (de) 2007-09-27
TWI244484B (en) 2005-12-01
JP3779153B2 (ja) 2006-05-24
CA2334249A1 (en) 1999-12-16
CN1312813A (zh) 2001-09-12
EP1086952A4 (en) 2005-02-02
AU764582B2 (en) 2003-08-21
AU4060699A (en) 1999-12-30
US6531148B1 (en) 2003-03-11
WO1999064424A1 (en) 1999-12-16
JP2006117662A (ja) 2006-05-11
KR20060086454A (ko) 2006-07-31
EP1086952A1 (en) 2001-03-28
CN1131867C (zh) 2003-12-24

Similar Documents

Publication Publication Date Title
KR100735139B1 (ko) 글리세로-1,5-에폭시-1αβ,6-디하이드록시-시스-헥스-3-엔-2-온 또는 유도체를 함유하는 세포자멸 유도용 조성물
KR100544856B1 (ko) 조류 유래의 생리활성물질을 이용한 의약, 식품 또는 음료
JPWO1999024447A1 (ja) 藻類由来の生理活性物質を利用した医薬、食品または飲料
JPWO1999064424A1 (ja) 治療剤
KR100582159B1 (ko) 사이클로펜테논, 이의 제조방법 및 용도
TW577744B (en) Medicinal compositions containing 3,6-anhydrogalactopyranose as active ingredient
JP2007326864A (ja) 医薬組成物
CN100584336C (zh) 医药组合物
JPWO2000043018A1 (ja) 医薬組成物

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20100628

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100628

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000